Jaina Patel was in her early 30s when a bout of bronchitis led to hear losing weight, her job and eventually her sense of smell - until a clinical trial worked wonders ...

Among patients with severe asthma receiving dupilumab for 12 months, 91% had a clinical response and 30% achieved clinical remission.

Dupilumab in combination with other biologic agents is safe and effective for treating various chronic inflammatory conditions.

Considering dual biologic therapy for psoriasis or eczema? Get a firsthand account of navigating insurance, potential side effects, and treatment outcomes.

Substantial challenges characterise the management of chronic obstructive pulmonary disease (COPD), including a progressively increasing symptom burden, exercise limitations, and frequent ...

Dupilumab improved nasal polyp outcomes and asthma symptoms more than omalizumab in patients with CRSwNP and asthma, according to the head-to-head EVEREST phase 4 trial.

In a phase 4 trial, dupilumab effectively reduces airway inflammation and mucus plugging, improving lung function and asthma control in patients with moderate to severe type 2 asthma.

Dupilumab significantly reduced the risk of exacerbations compared with placebo in children with moderate to severe asthma, regardless of exacerbation history.

Dupilumab shows long-term efficacy across yearly seasons in patients with type 2 inflammatory asthma.

Long-term treatment with dupilumab appeared effective among patients with asthma with or without coexisting chronic rhinosinusitis with nasal polyps, according to a study published in Annals of ...

Patients with asthma who received dupilumab experienced a significant decrease in asthma exacerbations vs omalizumab, benralizumab, or mepolizumab.

In a study of house dust mite–related asthma and allergic rhinitis, combining sublingual immunotherapy with dupilumab improved asthma control in 70% of patients.